Transcript
Page 1: Novel Antibody Libraries for Therapeutic Antibody Discoveryabdesignlabs.com/content/publications/AET San Diego 2018.pdf · ALTHEA Gold Libraries™ Novel Antibody Libraries for Therapeutic

ALTHEA Gold Libraries™ Novel Antibody Libraries for Therapeutic Antibody

Discovery

Abstract

Philippe Valadon1, Renae Nelson1

1 Antibody Design Labs, San Diego, CA 92121

Philippe Valadon1, Sonia M. Pérez-Tapia2, Renae S. Nelson1, Omar U. Guzmán-Bringas2, Hugo I. Arrieta-Oliva2, Keyla M. Gómez-Castellano2, Mary Ann Pohl3, Juan C. Almagro4

1 Antibody Design Labs, San Diego, CA 92121 3 Tri-Institutional Therapeutics Discovery Institute, New York, NY 10021 2 UDIBI, ENCB, Instituto Politécnico Nacional, México 2009-2013 4 GlobalBio Inc., Cambridge, MA 02138

Multi-stage Antibody Library Construction

ALTHEA Gold libraries™

ALTHEA Gold Libraries™ are highly diversified scFv libraries (> 1010 cfu each) enriched for developable antibodies resulting from the combination of in

vitro selected scaffolds with in vivo validated CDR-H3 diversity.

Flat scaffold for protein targets

Grooved scaffold for peptide targets

3-23/3-20 PDB: 5I1i

3-23/4-1 PDB: 5I1d

Alternative Topographies to Bind Protein and Peptide Targets

The shape of the antigen-binding site determines the type of the antigen the antibody interacts with.

Finlay & Almagro. Front Immunol. 3:342, 2012

ALTHEA Gold Libraries™ scaffolds provide two alternative antigen-binding site topographies: One flat suitable for protein antigens and the

other grooved biased towards the recognition of peptides.

Antigen-binding site

Protein-A

The VH scaffolds binds Protein-A and enables filtration of well-folded antibodies. One of the VL binds Protein-L and enables assay

development and identification of variants coming out of the anti-peptide libraries when used combined with the anti-protein library

Also…

Biopanning with Protein Models

Quality Control of ALTHEA Gold Libraries™

Summary

Easy to analyze

Highly Diverse

Developable antibodies

>1010 members

Two alternative topographies +

CDR-H3 with a Gaussian distribution of lengths from 1 to 20

Highly stable (Tm >700C)

One universal VH scaffold Two alternative VL scaffolds

Known structures Protein-A/L binding

~70% (>7 x 109) unique & functional antibody fragments

Philippe Valadon, M.D., Ph.D. [email protected] Tel: +1.858.480.6213 www.abdesignlabs.com

Juan C. Almagro, Ph.D. [email protected] Tel: +1.617.710.4487 www.globalbioinc.com

For Information, please contact:

Each set of ALTHEA Gold Libraries™ is unique, combining carefully designed human scaffolds of improved developability with natural CDR-H3 diversity. Please direct your inquiry for ownership to Antibody Design Labs or GlobalBio, Inc.

Protein-A : scFv complex PDB: 1dee

Protein-L : scFv complex PDB: 1mhh

Deep Sequencing of Over One Million of H3J fragments

0

2

4

6

8

10

12

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Anti-Protein

Anti-Peptide

The potential of ALTHEA Gold Libraries™ to generate specific and diverse antibodies has successfully been validated with

several undisclosed targets, including a soluble target, a peptide/protein complex and a membrane protein

After reshuffling natural H3J diversity from the pool of 200 donors into selected scFvs for high stability in the primary libraries, all the clones are unique, with

~70% being highly stable

Frequency (%)

CDR-H3 length (Kabat’s definition)

0

10

20

30

40

Anti-Protein

Anti-Peptide

Human IGHJ germline gene usage

Frequency (%)

We present here, the design, implementation and validation of ALTHEA (from the Greek “to heal”) Gold Libraries™. ALTHEA Gold Libraries™ are semisynthetic scFv libraries built on synthetic human well-known VH and VL germline genes combined with natural H3J fragments obtained from a pool of 200 human donors. The three germline genes provide a universal VH scaffold paired with two distinct VL scaffolds. The VL scaffolds offer two alternative antigen-binding site topographies to bind protein or peptide targets. The antigen-binding site (except the CDR-H3) diversity is designed in positions identified as in contact with protein and peptide antigens in the known antigen-antibody complex structures. The diversification regimes are designed based on the amino acid frequencies of the repertoire of human germline genes and known human antibody sequences. Through a proprietary process comprising the selection for thermostable scFv variants, followed by shuffling of the natural H3J fragments, ALTHEA Gold Libraries™ provide a highly diverse, functional and developable repertoire of human antibody fragments suitable for antibody therapeutic discovery and development. The potential of ALTHEA Gold Libraries™ to generate specific antibody fragments has been assessed with multiple targets including protein models (Hen Egg White Lysozyme; HEL, Human Serum Albumin; HSA), several therapeutic targets including TNF, a protein/peptide complex, and membrane proteins. In all case studies, diverse and specific antibodies were obtained with Kd in the low nM range.

Carefully designed scaffolds with neutral CDR-H3 fragments,

displayed as scFvs

Heat shock

Highly stable scFv library

Rescue with Protein A

200 donors Age < 40 years

100 males & 100 females

RT-PCR

with specific

primers

10 min @ 700C

Diverse H3J fragments

Primary Libraries Natural H3J fragments

Sfi I

VH (3-23)

CDR-H3 +

Joining

Linker GS19 Vk (3-20/4-1)

PelB

Sfi I

Neutral/Natural

Diversity

~ 100 bp

Synthetic

~ 800 bp

Tags Designed Diversity Designed Diversity

Diversity: 106 Diversity: 106

Protein-L

Antigen-binding site

HEL-coated

Immunotubes

100 ug/mL

TDI libraries

Washed away

non-bound Ф

bound Ф

Eluted with Trypsin

Rescued

with helper Ф

Anti-Protein

or

Anti-Peptide

(1012 Ф) ~100x coverage

Plated in 2xYT/Carb

Human Serum Albumin ALTHEA Gold Libraries™ SL2 by Direct Capture

Yield specific scFvs against multiple targets using diverse

biopanning strategies Highly functional

Ph

ag

eo

utp

ut

(UFC

/ml )

x 10 5

0

100

200

300

400

500

600

700

800

Round 1 Round 2 Round 3 Round 4

0

200

400

600

800

1000

1200

1400

1600

Round 1 Round 2 Round 3 Round 4

Lysozyme Parallel Biopanning of the Anti-protein and Anti-peptide Libraries and Trypsin Elution

Protein-A binding after 720C (10 min)

Carefully Designed Diversity

Identified positions in contact with protein and peptide targets and diversified based on human germline genes and known antibody sequences amino acid frequencies

0%

15%

30%

45%

1.20 - 1.49 1.50 - 1.99 2.00 - 2.49 2.50 - 3.00

RESOLUTION

> 50% below 3.0 Å

Macaca mulatta

Rattus norvegicus

Humanized

Chimeric

Mus musculus

Homo sapiens

SPECIES

Anti-Protein

Anti-Peptide

GENERAL SPECIFITIES

Studied over 2,500 antibodies known structure to design ALTHEA Gold Libraries™

CDR-H3

VL

900

VH

0%

20%

40%

60%

80%

100%

ǁ A

1

ǁ B

1

ǁ C

1

ǁ D

1

ǁ E1

# F

1

ǁ G

1

ǁ H

1

ǁ A

2

ǁ B

2

ǁ C

2

ǁ D

2

ǁ E2

ǁ F2

ǁ G

2

# H

2

A3

ǁ B

3 C3

ǁ D

3

ǁ E3

ǁ F3

ǁ G

3

# H

3

ǁ A

4

ǁ B

4

ǁ C

4

ǁ D

4

ǁ E4

ǁ F4

ǁ G

4

H4

A5

ǁ B

5

ǁ C

5

ǁ D

5

ǁ E5 F5

ǁ G

5

ǁ H

5

ǁ A

6

B6

ǁ C

6

ǁ D

6

3-2

0/3

-23

3-2

0/3

-23

TB

S

TB

S

= In-frame

0%

20%

40%

60%

80%

100%

ǁ A

1

ǁ B

1

ǁ C

1

ǁ D

1 E1

ǁ F1

ǁ G

1

H1

A2

ǁ B

2

ǁ C

2

ǁ D

2

ǁ E2

ǁ F2

ǁ G

2

# H

2

ǁ A

3

ǁ B

3

ǁ C

3

ǁ D

3

# E

3

ǁ F3

ǁ G

3

ǁ H

3

ǁ A

4

ǁ B

4

ǁ C

4

ǁ D

4

ǁ E4

ǁ F4 G

4

# H

4

ǁ A

5

ǁ B

5

ǁ C

5

ǁ D

5

ǁ E5

# F

5

ǁ G

5

ǁ H

5

ǁ A

6

ǁ B

6

ǁ C

6

D6

4-0

1/3

-…

4-0

1/3

-…

TB

S

TB

S

Biopanning and Screening

Selection

Specific Clones Amplification

Further Characterization

RAM kit™ if needed

Positive Clones Screening

ALTHEA Gold Libraries™

L1 L2 L3

L1 L2 L3

Diversified Synthetic Scaffolds Sequence Diversity

H1 H2

H1 H2

In-frame

indels

0

0.2

0.4

0.6

0.8

1

1.2

4.00E+08 4.00E+09 4.00E+10 4.00E+11

R1

R2

R3

R4

3-20/3-23 (-)

0

0.2

0.4

0.6

0.8

1

1.2

4.00E+08 4.00E+09 4.00E+10 4.00E+11

R1

R2

R3

R4

3-20/3-23 (-)

cfu x 105 cfu x 105

OD

Φ/mL

OD

Anti-protein

Anti-peptide

Anti-peptide

Anti-protein

Summary of the Biopanning Results: Hit rate 80% after 3 rounds

BSA HEL

Titre Polyclonal ELISA

Amplicon 2 SL1 % SL2 %

Total sequences 1,077,746 100.00 1,227,176 100.00

Accepted sequences 853,327 79.0 990,864 80.7

Unique sequences 851,681 99.8 989,005 99.8

Unique CDR-H3 sequences 522,939 61.3 592,317 59.8

0.048 0.599 0.045 0.045 0.045 0.045 0.81 0.873 0.868 0.85 0.742 0.68

0.041 0.041 0.041 0.041 0.546 0.042 0.783 0.87 0.882 0.851 0.583 0.69

0.05 0.059 0.046 0.047 0.055 0.047 0.826 0.902 1.03 0.865 0.753 0.723

0.047 0.045 0.045 0.045 0.561 0.743 0.819 0.92 0.919 0.841 0.571 0.726

0.048 0.046 0.045 0.045 0.044 0.717 0.601 0.933 0.894 0.851 0.795 0.727

0.042 0.04 0.691 0.039 0.041 0.04 0.838 0.919 0.751 0.851 0.806 0.782

0.17 0.044 0.044 0.044 0.044 0.045 0.239 0.917 0.892 0.826 0.818 0.801

0.044 0.042 0.043 0.043 0.048 0.295 0.982 0.951 0.914 0.907 0.853 0.275

0

0.05

0.1

0.15

0.2

0.25

0.3

0.35

0.4

0.45

0.5

1 2 3 4 5 6 7 8 9 10 11 12

Clone 11

Clone 5

Clone 3

(-)

Dilutions

3 clones EC50 40-100 nM by ELISA

Best clones HSA-B3 Kd 3.3 nM as Fab

Top Related